IL-35在HBV感染所致疾病中的调控作用和相关机制

杨晓飞; 连建奇; 张野

doi:10.3969/j.issn.1001-5256.2022.05.036

IL-35在HBV感染所致疾病中的调控作用和相关机制

DOI: 10.3969/j.issn.1001-5256.2022.05.036

空军军医大学第二附属医院(第四军医大学唐都医院) 传染科，西安 710038

基金项目:

国家自然科学基金 (31370856);

国家自然科学基金 (81671555);

艾滋病和病毒性肝炎等重大传染病防治国家科技重大专项 (2017ZX10202203-007-003);

艾滋病和病毒性肝炎等重大传染病防治国家科技重大专项 (2017ZX10105011-004)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：杨晓飞负责拟定写作思路，检索文献，撰写论文; 连建奇、张野负责指导、修改论文并最终定稿。

详细信息

通信作者:
张野，zhangyefmmu@hotmail.com

计量
- 文章访问数: 607
- HTML全文浏览量: 180
- PDF下载量: 57
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-09
- 出版日期: 2022-05-20

Role and mechanism of interleukin-35 in hepatitis B virus-related diseases

Department of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University & The Second Affiliated Hospital of Air Force Medical University, Xi'an 710038, China

Research funding:

National Natural Science Foundation of China (31370856);

National Natural Science Foundation of China (81671555);

National Science and Technology Major Project of China for Prevention and Treatment of Serious Infectious Diseases (2017ZX10202203-007-003);

National Science and Technology Major Project of China for Prevention and Treatment of Serious Infectious Diseases (2017ZX10105011-004)

More Information

Corresponding author: ZHANG Ye, zhangyefmmu@hotmail.com(ORCID: 0000-0002-2573-5471)

摘要

摘要: IL-35主要是由调节性T淋巴细胞和调节性B淋巴细胞分泌的抑制性细胞因子，参与感染、肿瘤、自身免疫性疾病的发病。本文归纳了IL-35在HBV感染所致的乙型肝炎、肝硬化、肝衰竭和肝细胞癌中的免疫调节作用和机制。分析表明IL-35在HBV感染所致疾病中发挥双刃剑作用，促进感染慢性化和肝细胞癌疾病进展，也可降低肝脏炎症损伤，抑制肝纤维化。
- 乙型肝炎病毒 /
- 白细胞介素类 /
- 免疫调节
Abstract: Interleukin-35 (IL-35) is an immunosuppressive cytokine mainly secreted by regulatory T cells and regulatory B cells and is involved in the pathogenesis of infectious diseases, tumors, and autoimmune diseases. This article summarizes the immunoregulatory role and mechanism of IL-35 in hepatitis B, liver cirrhosis, liver failure, and hepatocellular carcinoma caused by hepatitis B virus (HBV) infection. The analysis shows that IL-35 is a "double-edged sword" in HBV-related diseases, and it can not only promote the chronicity of infection and the progression of hepatocellular carcinoma, but also alleviate liver inflammation and inhibit liver fibrosis.
- Hepatitis B virus /
- Interleukins /
- Immunomodulation

HTML全文

图 1 IL-35在HBV感染相关疾病中的作用和机制

Figure 1. Role and mechanism of IL-35 in HBV infection related diseases

下载: 全尺寸图片幻灯片

参考文献(52)

[1]	CHOI JK, EGWUAGU CE. Interleukin 35 regulatory B cells[J]. J Mol Biol, 2021, 433(1): 166607. DOI: 10.1016/j.jmb.2020.07.019.
[2]	LIU K, HUANG A, NIE J, et al. IL-35 regulates the function of immune cells in tumor microenvironment[J]. Front Immunol, 2021, 12: 683332. DOI: 10.3389/fimmu.2021.683332.
[3]	XIN PL, JIE LF, CHENG Q, et al. Pathogenesis and function of interleukin-35 in rheumatoid arthritis[J]. Front Pharmacol, 2021, 12: 655114. DOI: 10.3389/fphar.2021.655114.
[4]	LI X, LIU X, WANG W. IL-35: A novel immunomodulator in hepatitis B virus-related liver diseases[J]. Front Cell Dev Biol, 2021, 9: 614847. DOI: 10.3389/fcell.2021.614847.
[5]	HU S, LIAN PP, HU Y, et al. The role of IL-35 in the pathophysiological processes of liver disease[J]. Front Pharmacol, 2020, 11: 569575. DOI: 10.3389/fphar.2020.569575.
[6]	TAIT WOJNO ED, HUNTER CA, STUMHOFER JS. The immunobiology of the Interleukin-12 family: Room for discovery[J]. Immunity, 2019, 50(4): 851-870. DOI: 10.1016/j.immuni.2019.03.011.
[7]	COLLISON LW, WORKMAN CJ, KUO TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function[J]. Nature, 2007, 450(7169): 566-569. DOI: 10.1038/nature06306.
[8]	BEHZADI P, BEHZADI E, RANJBAR R. IL-12 family cytokines: General characteristics, pathogenic microorganisms, receptors, and signalling pathways[J]. Acta Microbiol Immunol Hung, 2016, 63(1): 1-25. DOI: 10.1556/030.63.2016.1.1.
[9]	DIXON KO, van der KOOIJ SW, VIGNALI DA, et al. Human tolerogenic dendritic cells produce IL-35 in the absence of other IL-12 family members[J]. Eur J Immunol, 2015, 45(6): 1736-1747. DOI: 10.1002/eji.201445217.
[10]	COLLISON LW, DELGOFFE GM, GUY CS, et al. The composition and signaling of the IL-35 receptor are unconventional[J]. Nat Immunol, 2012, 13(3): 290-299. DOI: 10.1038/ni.2227.
[11]	DAMBUZA IM, HE C, CHOI JK, et al. IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease[J]. Nat Commun, 2017, 8(1): 719. DOI: 10.1038/s41467-017-00838-4.
[12]	LIU J, HAO S, CHEN X, et al. Human placental trophoblast cells contribute to maternal-fetal tolerance through expressing IL-35 and mediating iT(R)35 conversion[J]. Nat Commun, 2019, 10(1): 4601. DOI: 10.1038/s41467-019-12484-z.
[13]	WANG W, WEI C, CHENG Z, et al. Aberrant Th2 immune responses are associated with a reduced frequency of IL-35-induced regulatory T cells after allergen exposure in patients with allergic asthma[J]. Allergy Asthma Immunol Res, 2020, 12(6): 1029-1045. DOI: 10.4168/aair.2020.12.6.1029.
[14]	GUO H, ZHAO N, GAO H, et al. Mesenchymal stem cells overexpressing interleukin-35 propagate immunosuppressive effects in mice[J]. Scand J Immunol, 2017, 86(5): 389-395. DOI: 10.1111/sji.12613.
[15]	LI Y, PAN X, PENG X, et al. Adenovirus-mediated interleukin-35 gene transfer suppresses allergic airway inflammation in a murine model of asthma[J]. Inflamm Res, 2015, 64(10): 767-774. DOI: 10.1007/s00011-015-0858-1.
[16]	TEYMOURI M, PIRRO M, FALLARINO F, et al. IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases[J]. Int J Cancer, 2018, 143(9): 2105-2115. DOI: 10.1002/ijc.31382.
[17]	XUE H, LIN F, TAN H, et al. Overrepresentation of IL-10-expressing B cells suppresses cytotoxic CD4⁺ T cell activity in HBV-induced hepatocellular carcinoma[J]. PLoS One, 2016, 11(5): e0154815. DOI: 10.1371/journal.pone.0154815.
[18]	DAMO M, JOSHI NS. T(reg) cell IL-10 and IL-35 exhaust CD8(+) T cells in tumors[J]. Nat Immunol, 2019, 20(6): 674-675. DOI: 10.1038/s41590-019-0389-y.
[19]	CHENG ST, YUAN D, LIU Y, et al. Interleukin-35 level is elevated in patients with chronic hepatitis B virus infection[J]. Int J Med Sci, 2018, 15(2): 188-194. DOI: 10.7150/ijms.21957.
[20]	RIBEIRO C, MARTINELLI KG, de MELLO V, et al. Cytokine, genotype, and viral load profile in the acute and chronic hepatitis B[J]. Viral Immunol, 2020, 33(10): 620-627. DOI: 10.1089/vim.2020.0176.
[21]	ZHOU Y, ZHANG H, LI Y. IL-35 expression in peripheral blood CD4(+) T cells from chronic hepatitis B virus-infected patients directly correlates with virus load[J]. Cytokine, 2015, 73(1): 169-175. DOI: 10.1016/j.cyto.2015.02.003.
[22]	TAO NN, GONG R, CHEN X, et al. Interleukin-35 stimulates hepatitis B virus transcription and replication by targeting transcription factor HNF4α[J]. J Gen Virol, 2018, 99(5): 645-654. DOI: 10.1099/jgv.0.001050.
[23]	YANG J, MA C, ZHAO Y, et al. Hepatitis B virus core particles containing a conserved region of the G Protein Combined with Interleukin-35 protected mice against respiratory syncytial virus infection without vaccine-enhanced immunopathology[J]. J Virol, 2020, 94(13): e00007-20. DOI: 10.1128/JVI.00007-20.
[24]	LIU Y, LUO Y, ZHU T, et al. Regulatory B cells dysregulated T cell function in an IL-35-dependent way in patients with chronic hepatitis B[J]. Front Immunol, 2021, 12: 653198. DOI: 10.3389/fimmu.2021.653198.
[25]	WAN Z, ZHOU Z, LIU Y, et al. Regulatory T cells and T helper 17 cells in viral infection[J]. Scand J Immunol, 2020, 91(5): e12873. DOI: 10.1111/sji.12873.
[26]	SHAO X, MA J, JIA S, et al. Interleukin-35 suppresses antiviral immune response in chronic hepatitis B virus infection[J]. Front Cell Infect Microbiol, 2017, 7: 472. DOI: 10.3389/fcimb.2017.00472.
[27]	YANG L, JIA S, SHAO X, et al. Interleukin-35 modulates the balance between viral specific CD4(+)CD25(+) CD127(dim/-) regulatory T cells and T helper 17 cells in chronic hepatitis B virus infection[J]. Virol J, 2019, 16(1): 48. DOI: 10.1186/s12985-019-1158-0.
[28]	TENG DK, LIU Y, LV YF, et al. Elevated interleukin-35 suppresses liver inflammation by regulation of T helper 17 cells in acute hepatitis B virus infection[J]. Int Immunopharmacol, 2019, 70: 252-259. DOI: 10.1016/j.intimp.2019.02.048.
[29]	MCLANE LM, ABDEL-HAKEEM MS, WHERRY EJ. CD8 T cell exhaustion during chronic viral infection and cancer[J]. Annu Rev Immunol, 2019, 37: 457-495. DOI: 10.1146/annurev-immunol-041015-055318.
[30]	LI X, TIAN L, DONG Y, et al. IL-35 inhibits HBV antigen-specific IFN-γ-producing CTLs in vitro[J]. Clin Sci (Lond), 2015, 129(5): 395-404. DOI: 10.1042/CS20140511.
[31]	DONG Y, LI X, YU Y, et al. JAK/STAT signaling is involved in IL-35-induced inhibition of hepatitis B virus antigen-specific cytotoxic T cell exhaustion in chronic hepatitis B[J]. Life Sci, 2020, 252: 117663. DOI: 10.1016/j.lfs.2020.117663.
[32]	XIANG XG, XIE Q. IL-35: A potential therapeutic target for controlling hepatitis B virus infection[J]. J Dig Dis, 2015, 16(1): 1-6. DOI: 10.1111/1751-2980.12218.
[33]	LUO M, PENG H, CHEN P, et al. The immunomodulatory role of interleukin-35 in fibrotic diseases[J]. Expert Rev Clin Immunol, 2019, 15(4): 431-439. DOI: 10.1080/1744666X.2019.1564041.
[34]	LI T, HUANG Y, LIU P, et al. Lower plasma levels of IL-35 in patients with primary biliary cirrhosis[J]. Tohoku J Exp Med, 2018, 244(2): 123-131. DOI: 10.1620/tjem.244.123.
[35]	SHI M, WEI J, DONG J, et al. Function of interleukin-17 and -35 in the blood of patients with hepatitis B-related liver cirrhosis[J]. Mol Med Rep, 2015, 11(1): 121-126. DOI: 10.3892/mmr.2014.2681.
[36]	HU H, FU Y, LI M, et al. Interleukin-35 pretreatment attenuates lipopolysaccharide-induced heart injury by inhibition of inflammation, apoptosis and fibrotic reactions[J]. Int Immunopharmacol, 2020, 86: 106725. DOI: 10.1016/j.intimp.2020.106725.
[37]	TSUDA M, ZHANG W, YANG GX, et al. Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type Ⅱ mice[J]. Hepatology, 2013, 57(2): 806-816. DOI: 10.1002/hep.25829.
[38]	WANG W, GUO H, LI H, et al. Interleukin-35 Gene-modified mesenchymal stem cells protect concanavalin A-induced fulminant hepatitis by decreasing the interferon gamma level[J]. Hum Gene Ther, 2018, 29(2): 234-241. DOI: 10.1089/hum.2017.171.
[39]	KODA Y, NAKAMOTO N, CHU PS, et al. Plasmacytoid dendritic cells protect against immune-mediated acute liver injury via IL-35[J]. J Clin Invest, 2019, 129(8): 3201-3213. DOI: 10.1172/JCI125863.
[40]	CHEN L, SUN W, WANG Y, et al. Lower levels of interleukin-35 in patients with prophase of liver failure are associated with progression to liver failure[J]. Ann Palliat Med, 2021, 10(8): 9174-9183. DOI: 10.21037/apm-21-1680.
[41]	YANG L, ZHANG Q, SONG J, et al. Interleukin-35 suppresses CD8(+) T cell activity in patients with viral hepatitis-induced acute-on-chronic liver failure[J]. Dig Dis Sci, 2020, 65(12): 3 614-3623. DOI: 10.1007/s10620-020-06077-w.
[42]	GAO Y, LIANG ZJ, FU J. Influence of interleukin-35 on peripheral CD8⁺ T cell function in patients with acute-on-chronic liver failure[J]. J Clin Hepatol, 2019, 35(9): 2011-2016. DOI: 10.3969/j.issn.1001-5256.2019.09.025. 高艺, 梁志军, 符健. IL-35对慢加急性肝衰竭患者外周血CD8⁺T淋巴细胞功能的影响[J]. 临床肝胆病杂志, 2019, 35(9): 2011-2016. DOI: 10.3969/j.issn.1001-5256.2019.09.025.
[43]	KOURKO O, SEAVER K, ODOARDI N, et al. IL-27, IL-30, and IL-35: A cytokine triumvirate in cancer[J]. Front Oncol, 2019, 9: 969. DOI: 10.3389/fonc.2019.00969.
[44]	LIU K, HUANG A, NIE J, et al. IL-35 regulates the function of immune cells in tumor microenvironment[J]. Front Immunol, 2021, 12: 683332. DOI: 10.3389/fimmu.2021.683332.
[45]	XUE W, YAN D, KAN Q. Interleukin-35 as an emerging player in tumor microenvironment[J]. J Cancer, 2019, 10(9): 2074-2082. DOI: 10.7150/jca.29170.
[46]	LONG J, GUO H, CUI S, et al. IL-35 expression in hepatocellular carcinoma cells is associated with tumor progression[J]. Oncotarget, 2016, 7(29): 45678-45686. DOI: 10.18632/oncotarget.10141.
[47]	FU YP, YI Y, CAI XY, et al. Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection[J]. Br J Cancer, 2016, 114(7): 767-776. DOI: 10.1038/bjc.2016.47.
[48]	HE Y, PEI JH, LI XQ, et al. IL-35 promotes EMT through STAT3 activation and induces MET by promoting M2 macrophage polarization in HCC[J]. Biochem Biophys Res Communl, 2021, 559: 35-41. DOI: 10.1016/j.bbrc.2021.04.050.
[49]	LIU X, REN H, GUO H, et al. Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma[J]. Clin Exp Immunol, 2021, 203(2): 219-229. DOI: 10.1111/cei.13535.
[50]	YANG L, SHAO X, JIA S, et al. Interleukin-35 dampens CD8(+) T cells activity in patients with non-viral hepatitis-related hepatocellular carcinoma[J]. Front Immunol, 2019, 10: 1032. DOI: 10.3389/fimmu.2019.01032.
[51]	ZHANG Q, YANG L, LIU S, et al. Interleukin-35 suppresses interleukin-9-secreting CD4(+) T cell activity in patients with hepatitis B-related hepatocellular carcinoma[J]. Front Immunol, 2021, 12: 645835. DOI: 10.3389/fimmu.2021.645835.
[52]	YAZDANI Z, RAFIEI A, GOLPOUR M, et al. IL-35, a double-edged sword in cancer[J]. J Cell Biochem, 2020, 121(3): 2064-2076. DOI: 10.1002/jcb.29441.